Kornimate/medical-research-clean huggingface dataset:
investigation of predictors of typing performance in office employees with neck pain

Conditions: Task Performance and Analysis

Summary: determining the predictors that are effective on work performance and preventive approaches to be developed for these predictors must be individual and adaptable to every environment, time, and equipment. in this context, the purpose of the present study was to show the relations between neck disability, upper trapezius (ut) muscle activation, posture, and demographic characteristics with typing task performance in office employees who have neck pain by using their equipment in their workplaces.

the present study was conducted to show the relations between neck disability, ut muscle activation, posture, and demographic characteristics with typing task performance in office employees who have neck pain by using their equipment in their workplaces. we hypothesized that ut muscle activation, working posture, and age might be the main predictors of typing performance in office employees with neck pain. for this purpose, full-time office employees who use computers for at least 3 hours a day and have neck pain were invited to the study. volunteers without any health concern, upper-body injury, and surgery provided informed, written consent to participate in the study. the participants were given a 10-minute typing task in their working environments, during which right and left ut muscle activation was recorded with surface electromyography (semg). work posture was evaluated with rapid upper limb assessment (rula) and forward head posture (fhp) was evaluated with cervical range of motion (crom) device. hierarchical regression analysis was conducted to examine the predictors of typing performance.

Eligibility criteria:
inclusion criteria: * full-time and regular employees in the last 1 year, * office employees use computers at desk for at least 3 hours per day * according to rula, working in a posture that is above the acceptable level, * no trauma history * non-specific neck pain but no chronic conditions of the cervical spine and upper extremity exclusion criteria: * volunteer office employees with neck pain who did not meet the inclusion criteria and those who could not complete the study because of pain, discomfort, etc. were excluded from the study (dropouts; n=3 because of pain and discomfort, n=1 because of incomplete evaluations not completed on their own will)

Keywords: neck pain office employees task- specific performance surface electromyography trapezius muscle forward head posture posture
glue application in the treatment of low-output fistulas

Conditions: Low-output External Gastrointestinal Fistula

Summary: adjuvant use of fibrin glue (fg) in the fistula tract has been shown to promote closure of low-output enterocutaneous fistulas (ecfs). the primary objectives of this study are to compare the clinical efficacy, safety of autologous platelet-rich fibrin glue (prfg), commercial fibrin glue, and control therapy in the management of patients with low-output volume ecfs.

* this is a prospective, randomized, multi-centered study clinical, safety and economic outcome of ecfs patients. * subjects are randomized to one of 3 groups: * group 1: autologous prfg-treatment \[prfg + standard of care (soc)\] * group 2: commercial fg-treatment \[fg + standard of care (soc)\] * group 3: control (soc only) * study will include three phases: * phase 1: screening, consent and enrollment * phase 2: patients will receive either prfg, commercial fg, or soc only for 14 days * phase 3: follow up: for patients with closed fistula within 14 days, we will follow up them for 6 months. for patients whose fistulas were still open will be treated with other therapeutic option and follow up for 6 months after closure.

Eligibility criteria:
inclusion criteria: * patients with a single tubular ecf * low output volume (\<200 ml/24h) * tract length \>2cm * tract diameter \< 1cm exclusion criteria: * cancer-infiltrated fistula * abscess * foreign bodies * distal bowel obstruction * inflammatory bowel disease

Keywords: autologous platelet rich fibrin glue enterocutaneous fistulas single low output gi fistulas
evaluation and treatment planning of patients with pap using thrive ultra short echo time mri and ct

Conditions: Pulmonary Alveolar Proteinosis

Summary: the purpose of this study is twofold: to assess routine cat scan (ct) imaging as a biomarker for removal of lipoprotein surfactant via lung lavage (where ct is the gold-standard imaging technique for density quantification), and to utilize a novel ute mri protocol to similarly quantify surfactant removal. this study will also serve to generate baseline scanning that may aid in developing analytical tools to evaluate and treat specific lung regions of patients with pap.

this study will evaluate x-ray ct as a biomarker for surfactant lavage removal and evaluate an ute-thrive mri protocol at cchmc as an imaging alternative to ct. potential subjects who meet study criteria will be identified by the pulmonary physicians at cincinnati children's hospital medical center (cchmc) and university of cincinnati (uc) through their clinic patients. the study will include two research mris (one pre lavage and the second 24 to 72 hours after the first lung lavage) and if there is a clinical ct performed pre lavage, then one research ct will also be performed with the second research mri. all image analysis will be quantitative. whole-lung and regional density will be calculated and evaluated before and after lung lavage, for a quantification of changes in density in the left lung and right lung separately. since the one lung will serve as control, it will allow precise error estimation (which we expect to be quite small and largely related to differences in lung volume). one purpose of this protocol is to further refine and develop ultra-short echo time (ute) mri techniques since pulmonary alveolar proteinosis (pap) patients may have multiple lavage sessions per year. a subject may be eligible to re-enroll to participate multiple times if the total number of research cts for all enrollments is one or less for that subject.

Eligibility criteria:
inclusion criteria: clinically diagnosed pap scheduled for lung lavage with double lumen endoscopy. * children patients ≥ 8 years of age * adult patients ≤ 75 years of age * medically stable as per the opinion of bruce trapnell, md or robert wood, md * patient and or parent consent obtained exclusion criteria: * standard mri exclusion criteria as set forth by the cchmc division of radiology * pregnancy

Keywords: pap pulmonary alveolar proteinosis pulmonary patients
a dose-ranging study to determine the efficacy, safety and tolerability of aerofact

Conditions: Respiratory Distress Syndrome in Premature Infant

Summary: the purpose of this two-part phase 2 study is to assess the safety, tolerability and efficacy of aerosolized sf-ri 1 (aerofact) when delivered via ncpap at two different doses.

part i primary objective to determine an optimal dose of aerofact administered by nasal continuous positive airway pressure (ncpap) versus stand of care in reducing the rate of intubation/cannulation and bolus surfactant instillation in the first 7 days after birth. part ii primary objective to evaluate pulmonary outcomes and respiratory utilization at 3, 6, 9, and 12 months post-menstrual age (pma)

Eligibility criteria:
inclusion criteria: 1. parental consent obtained prior to study procedures being performed (pre-natal consent is allowed) 2. 26 0/7 to 30 6/7 weeks of gestational age 3. weight \<2.0 kg 4. respiratory severity score (rss) 1.4-2.0 exclusion criteria: 1. apgar score less than or equal to 5 at five minutes after birth 2. need for chest compressions or administration of epinephrine or bicarbonate in the delivery room 3. premature rupture of membranes (prom) \> 14 days 4. need for intubation and/or mechanical ventilation prior to enrollment 5. active pneumothorax requiring chest tube 6. significant congenital anomaly, chromosomal abnormality 7. concomitant treatments with inhaled nitric oxide

Keywords: respiratory distress syndrome bpd surfactant preterm infant
quiting marijuana use: self-report study of quitting straegies and withdrawal symptoms

Conditions: Cannabis Abuse; Cannabis Dependence

Summary: background: - marijuana is the most widely used illicit drug in the world, yet relatively little is known about users who try to quit without formal treatment ( spontaneous quitting). studies have suggested that there are some common strategies that many individuals use in spontaneous quitting, such as changing one s lifestyle or identity, reminding oneself of negative consequences, support from family and friends, and religion. however, more research is needed to determine potential treatment strategies for marijuana use. objectives: * to identify strategies used to help with marijuana quitting among non-treatment seeking adult marijuana users. * to identify withdrawal symptoms experienced during marijuana quitting and their relationship to the quitting strategies used and the outcome of the quit attempt. * to evaluate whether subgroups of marijuana users differ in their experience of marijuana quitting. eligibility: - individuals at least 18 years of age who have made at least one attempt to quit marijuana use. design: * the study will consist of one visit of approximately 1 to 2 hours. * participants will fill out three questionnaires. the questionnaires have different types of questions, and will ask about background and lifestyle, marijuana use and craving patterns and behaviors, and difficulties in previous attempts to quit using marijuana.

marijuana is the most widely used illicit drug in the world, yet relatively little is known about users who try to quit without formal treatment (so-called spontaneous quitting). this study will use two self-report questionnaires to collect information on the socio-demographic characteristics, marijuana use history, most difficult marijuana quit experience, and marijuana craving from a convenience sample of 1230 adult, non-treatment-seeking marijuana users. the questionnaires take 45-60 minutes to administer. data will be analyzed for patterns and correlations among the characteristics of the quit attempt, including any withdrawal symptoms, quitting strategies used, and its success. the marijuana craving data will be analyzed to evaluate the validity of this measure of marijuana craving. there are no direct benefits to subjects from study participation. the scientific benefit is an improved understanding of spontaneous quitting of marijuana use, which may lead to improved interventions for marijuana users in the future. there are no physical risks to subjects. there are risks of anxiety or embarrassment while taking the questionnaire and of loss of confidentiality of sensitive information collected about subjects.

Eligibility criteria:
* inclusion criteria: 1. age 18 or older 2. have made at least one attempt to quit marijuana use 3. able to give valid informed consent 4. ability to understand english

Keywords: cannabis craving questionnaire non-treatment drug use
effort-lung ultra sound

Conditions: Heart Failure With Preserved Ejection Fraction

Summary: the e-lus study is a prospective, non randomised, monocenter case-control study. the main objective is to evaluate the association of exercise lung ultrasound data acquired during a stress test on a bicycle ergometer with the diagnosis of heart failure with preserved ejection fraction (hfpef).

secondary objectives: 1. to assess the diagnostic performance of exercise lung ultrasound for the diagnosis of hfpef. 2. to identify the value of the b-lines score on exercise maximizing the sensitivity and specificity for the diagnosis of hfpef. 3. to evaluate the relationship of the delta of b-lines scores between rest and exercise with the diagnosis of hfpef. 4. to assess the diagnostic performance of the delta of b-lines between rest and exercise for the diagnosis of hfpef. 5. to identify the score of the delta of b-lines value between rest and exercise maximizing sensitivity and specificity for the diagnosis of hfpef. 6. to evaluate the relationship between the resting value of the b-lines scores with the diagnosis of hfpef. 7. to assess the diagnostic performance of the resting lung ultrasound for the diagnosis of hfpef. 8. to identify the value of the b-lines score at rest maximizing the sensitivity and specificity for the diagnosis of hfpef. 9. to evaluate the correlation between the b-line score measured at rest and exercise and the dyspnoea score measured at rest, during exercise, and during the recovery phase. 10. to assess the correlation of the delta of b-lines scores between rest and exercise and the dyspnoea score measured at rest, during exercise and during the recovery phase.

Eligibility criteria:
inclusion criteria (control group) : * patients 65 years of age and older scheduled for a stress test. * never diagnosed with either preserved or altered ejection fraction heart failure * non-dyspneic (new york heart association class i) inclusion criteria (case group) : * patients 65 years of age and older scheduled for a stress test. * patients already diagnosed with hfpef following hospitalization for heart failure (lvef\>50%) exclusion criteria: * patients who are opposed to participate to the research project / the use of their data, * pulmonary or pleural pathology preventing reliable acquisition of lung ultrasound images (e.g. pulmonary fibrosis, diffuse interstitial lung disease or lung cancer) * patients with a history of thoracic surgery * patients under legal protection measures (guardianship, curator, judicial safeguard), * pregnant women, parturient women or nursing mothers, * patients who are unable to express consent, * persons deprived of their liberty by a judicial or administrative decision, * persons subject to psychiatric care, * patients discharged from hospital for a worsening heart failure hospitalization for less than 15 days
study of topical abi-1968 in subjects with precancerous anal lesions resulting from human papillomavirus (hpv) infection

Conditions: HSIL, High-Grade Squamous Intraepithelial Lesions; Human Papilloma Virus Infection; HIV Infection; Anal Cancer; Anus Neoplasms

Summary: this study evaluates the use of abi-1968, a topical cream, in the treatment of anal precancerous lesions in adults with and without human immunodeficiency virus (hiv) infection.


Eligibility criteria:
inclusion criteria: 1. female or male subjects, at least 27 years old. 2. confirmed diagnosis of intra-anal hsil at least 3 months prior to screening and confirmed by histopathology (with p16 positive staining) 3. intra-anal hsil are visible and evaluable by hra at the time of screening, and no lesion(s) is suspicious for invasive cancer. 4. for hiv-positive subjects, cd4 count must be at least 200/mm3 with undetectable (\<50 copies/ml) viral load within the 3 months prior to enrollment. subjects must be on a stable regimen of antiretroviral drugs for the 3 months prior to enrollment. exclusion criteria: 1. women who are pregnant, plan to become pregnant in the next 3 months, or lactating females. 2. received topical treatment or ablative procedures for ahsil in the 6 months prior to enrolment. 3. history of cancer, including anal cancer (with the exception of basal cell or squamous cell carcinoma of the skin), or currently undergoing treatment for any skin cancer. 4. history of genital herpes with \> 3 outbreaks per year. 5. plan to have excision or ablation of the lesion(s) within 3 months of enrolment.
prepception: expanding assisted reproductive options for serodiscordant couples

Conditions: PrEP for Conception Purposes

Summary: the purpose of this study is to observe patient response to current clinical practice utilizing truvada (emtricitabine and tenofovir disoproxil fumarate) for pre-exposure prophylaxis (prep) amongst hiv serodiscordant couples desiring to conceive across four u.s. cities that are currently offering this method as standard of care. this study is an observational cohort study, which will test the feasibility and acceptability of prep for conception, while examining the challenges and generalizability of this current medical practice. the cdc recently released formal clinical practice guidelines for the use of prep in the united states. for high-risk serodiscordant heterosexual couples using prep during conception, the guidelines state, "prep use periconception and during pregnancy by the uninfected partner may offer an additional tool to reduce the risk of sexual hiv acquisition. both the fda labeling information and the perinatal antiretroviral treatment guidelines permit this use" (cdc 2014).

based on cdc's guidance on prep as well as results of randomized controlled trials, the u.s. food and drug administration (fda) approved this daily medication (comprised of one pill) to reduce the risk of sexually acquired hiv in adults at high risk. other medical practices to avoid transmission within this population include assisted reproductive technologies such as sperm washing (or donated sperm) coupled with in vitro fertilization, intracytoplasmic sperm injection (an in vitro procedure where a single sperm is injected directly into an egg), and intrauterine insemination (placing the sperm directly into the uterus). however, these methods are costly and often regionally scarce. prep is more accessible and a less expensive option for couples. when used consistently and as prescribed, prep has shown to significantly reduce the risk of hiv infection among adult men and women. however, risk reduction counseling and clinical monitoring are necessary for its effective implementation. therefore, beyond efficacy trials, it is important to conduct additional studies of pre-exposure prophylaxis to observe what factors make prep feasible and acceptable to couples, as well as identify other factors that impact level of adherence. the study will take place in four u.s. cities: boston, baltimore, philadelphia, and san francisco and will involve couples who have chosen to begin prep for conception as part of their clinical care after receiving preconception counseling and reviewing their options with their health care provider.

Eligibility criteria:
inclusion criteria: * between the ages of 18 to 40 years * in relationship with hiv-positive male * chosen to take prep for conception after completing counseling with health care provider exclusion criteria: * hiv-positive * in relationship with hiv-negative female * partner has chosen to take prep for conception after completing counseling with health care provider

Keywords: prep conception hiv serodiscordant
study evaluating dvs sr in patients with fibromyalgia syndrome

Conditions: Fibromyalgia

Summary: the primary objective is to evaluate the long-term safety of desvenlafaxine succinate sustained-release (dvs sr) during open-label treatment in adult outpatients with fibromyalgia syndrome.

patients completing study 3151a4-327 have the opportunity to be treated with dvs sr during the 6 month extension study.

Eligibility criteria:
inclusion criteria: * outpatients who have completed double-blind treatment in study 3151a4-327 for fibromyalgia syndrome with no major protocol violations and no events that would preclude the patient's entry into the long-term open-label study. * women of childbearing potential must have a negative serum pregnancy test result at study start. exclusion criteria: * presence of any new/and or clinically important medical condition that might compromise patient's safety. * use of prohibited treatment. * meets any of the exclusion criteria listed for study 3151a4-327.
study of efficacy & safety for 3 infusion regimens of iv conivaptan in subjects with euvolemic or hypervolemic hyponatremia

Conditions: Hyponatremia

Summary: the study is designed to assess the efficacy and safety of multiple infusions of conivaptan in subjects with euvolemic or hypervolemic hyponatremia


Eligibility criteria:
inclusion criteria: * euvolemic or hypervolemic (edematous) based on clinical presentation * serum sodium between 115 and 130meq/l at baseline exclusion criteria: * clinical presentation of volume depletion or dehydration

Keywords: hyponatremia hypervolemic euvolemic edematous conivaptan
expanded access study of tas-102 in patients with metastatic colorectal cancer

Conditions: Colorectal Cancer Metastatic

Summary: the objective of the program is to provide access to tas-102 to patients with metastatic colorectal cancer who are refractory to or failing standard chemotherapy, are new to therapy with tas-102 and in whom therapy with tas-102 is clinically indicated.

this is an open-label study to provide expanded access to tas-102 prior to its commercial availability for patients with metastatic colorectal cancer who have been previously treated with, or are not candidates for fluoropyrimidine-, irinotecan-, and oxaliplatin-based chemotherapy, an anti-vascular endothelial growth factor (vegf) therapy, and an anti-epidermal growth factor receptor (egfr) therapy. serious adverse event information (whether or not related to tas-102) as well as reports of pregnancy, overdose, or medication error will reported. in addition, all grades of adverse drug reactions (adrs, adverse events related to study medication) and any adverse event that results in treatment discontinuation will be recorded as study data on crfs.

Eligibility criteria:
inclusion criteria: 1. has provided written informed consent 2. has adenocarcinoma of the colon or rectum 3. has failed at least 2 prior regimens of standard chemotherapies for metastatic colorectal cancer 4. ecog performance status of 0 or 1 5. is able to take medications orally 6. has adequate organ function (bone marrow, kidney and liver) 7. women of childbearing potential must have a negative pregnancy test and must agree to adequate birth control if conception is possible. males must agree to adequate birth control. exclusion criteria: 1. certain serious illnesses or medical condition(s) 2. has had certain other recent treatment e.g. major surgery, anticancer therapy, extended field radiation, received investigational agent, within the specified time frames prior to study drug administration 3. has received tas-102 4. has unresolved toxicity of greater than or equal to ctcae grade 2 attributed to any prior therapies 5. is a pregnant or lactating female